BioLineRx Director Raphael Hofstein's Stock Option Holdings Disclosure

This SEC Form 3 filing discloses the initial stock option holdings of BioLineRx Ltd. director Raphael Hofstein. The filing details 10 separate stock option grants awarded between 2016 and 2024, with exercise prices ranging from $0.052 to $0.920 per share. The options cover a total of 4,275,000 ordinary shares and were granted under the company's 2003 Amended and Restated Share Incentive Plan. Most options are fully vested, with the most recent October 2024 grant having 856,200 options vested immediately and 1,198,800 options vesting in quarterly installments. The securities are held through a trustee to qualify for Israeli tax benefits under Section 102 of the Israeli Tax Ordinance. This is a routine disclosure of director equity compensation holdings required for SEC compliance.